RhumbLine Advisers’s Orchestra BioMed OBIO Stock Holding History

RhumbLine Advisers’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$138K	Buy	+31,940	New	+$131K	﹤0.01%	3417
2025 Q2	–	Sell	-31,657	Closed	-$135K	–	4224
2025 Q1	$135K	Buy	31,657 +914	+3%	+$4.54K	﹤0.01%	3285
2024 Q4	$123K	Buy	30,743 +1,196	+4%	+$6.42K	﹤0.01%	3415
2024 Q3	$152K	Buy	29,547 +3,108	+12%	+$20.3K	﹤0.01%	3362
2024 Q2	$215K	Buy	26,439 +17,405	+193%	+$101K	﹤0.01%	3191
2024 Q1	$47.6K	Buy	9,034 +606	+7%	+$4.11K	﹤0.01%	3635
2023 Q4	$76.9K	Buy	8,428 +874	+12%	+$5.97K	﹤0.01%	3526
2023 Q3	$65.9K	Buy	7,554 +4,379	+138%	+$29.4K	﹤0.01%	3585
2023 Q2	$22.2K	Buy	+3,175	New	+$48.2K	﹤0.01%	3797

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

RhumbLine Advisers's OBIO Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Orchestra BioMed (OBIO) in Q2 2026: 31,940 shares worth $138K. The stake represents ﹤0.01% of the portfolio and ranks #3417 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in OBIO as recently as Q1 2025.

RhumbLine Advisers first reported a position in OBIO in Q2 2023 and has held it in 9 quarters since. The position peaked at $215K in Q2 2024. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

RhumbLine Advisers held 31,940 shares of Orchestra BioMed worth $138K as of Q2 2026.
Orchestra BioMed was a new RhumbLine Advisers position in Q2 2026.
Orchestra BioMed made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3417 holding.
RhumbLine Advisers first reported a position in Orchestra BioMed in Q2 2023 and has held it in 9 quarters since.
RhumbLine Advisers's Orchestra BioMed position peaked at $215K in Q2 2024.
77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.